• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura, Sparsha ink drug-delivery deal

September 27, 2019 By Sean Whooley

Nemaura Pharma said today that it entered into a strategic collaboration with Sparsha Pharma USA for the development and manufacturing of transdermal drug delivery systems.

The terms of the agreement state that Loughborough, England-based Nemaura will develop transdermal therapeutic systems at its facilities in the U.K., up to pilot clinical manufacture, for both global pharmaceutical companies and internally funded programs.

Sparsha Pharma is set to manufacture for Nemaura Pharma’s developments for the U.S., Canadian and Latin American markets. The FDA successfully audited Sparsha’s good manufacturing practice facility, deeming that the Oceanside, Calif.-based company’s facility has the capacity for end-to-end manufacturing of multiple transdermal patches and thin films for the American markets, according to a news release.

Nemaura Pharma said five of its 20 drugs in development are transdermal patches for various global multinationals, and the company has the manufacturing capabilities for patches and injectable drugs.

“We are delighted to enter into this strategic collaboration which brings together our formulation specialism for complex drug delivery systems and Sparsha’s wealth of experience in the manufacture of transdermal therapeutic systems to serve the largest global healthcare market, from their state of the art facility,” Nemaura Pharma CEO Dr. Faz Chowdhury said in prepared remarks.

“There are excellent synergies between Nemaura Pharma and Sparsha USA and this collaboration will allow us to utilize the complementary skills, expertise and resources of the two organizations and allow us to access a greater share of the market,” added Sparsha CEO Dange Veerapaneni.

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions Tagged With: Nemaura Pharma, Sparsha Pharma

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS